Blood
Articles in this Issue
Long-term risk of thromboembolic events in patients with post-acute sequelae of COVID-19: A retrospective propensity-matched cohort study
Abstract Background Post-acute sequelae of SARS-CoV-2 infection (PASC), commonly referred to as long COVID, is a clinical syndrome characteri...
The N6-methyladenosine methyltransferase wtap maintains erythropoiesis by stabilizing STAT5a mRNA
Abstract Anemia, a common global health problem, affects about more than 500 million people worldwide. N6-methyladenosine (m6A) methylation...
Autologous stem cell transplantation in Mantle Cell Lymphoma: Survival and the role of cytarabine in conditioning regimens
Abstract Introduction: Mantle cell lymphoma (MCL) is a rare and heterogeneous lymphoproliferative neoplasm characterized by frequent relapse...
Blinatumomab plus dasatinib in a dialysis-dependent patient with ph-positive B-ALL: Durable MRD-negative remission
Abstract Background & Rationale:Philadelphia-positive (Ph+) B-cell acute lymphoblastic leukemia (ALL) accounts for ~20–30% of adult ALL....
Early post-infusion cytokine profiling predicts toxicity and outcomes in recipients of NexCAR19 (Actalycabtagene Autoleucel): A pilot study with point-of-care assay integration
Abstract Background: CD19-directed CAR-T cell therapies have significantly improved outcomes in relapsed/refractory (R/R) B-cell malignancie...
Multi-omics unveils ER stress-driven pDC-like leukemia stem cells in pDC-AML
Abstract Introduction: Acute myeloid leukemia (AML) is characterized by aggressive proliferation, differentiation blockage, and heterogeneou...
Clinical efficacy and safety of daratumumab-carfilzomib based therapy in newly diagnosed multiple myeloma: A retrospective cohort analysis
Abstract Introduction: Carfilzomib (K) and daratumumab (D) combination has earning FDA approval for relapsed/refractory multiple myeloma. Th...
Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study
Abstract Background: Mosunetuzumab (Mosun), a CD20xCD3 T-cell engaging bispecific antibody, combined with polatuzumab vedotin (Pola), a CD79...
Therapy-related malignancies in myeloma: SEER comparison of IMiD vs anti-CD38 eras
Abstract Background Multiple myeloma (MM) is the second-most common hematologic cancer in the United States. Novel agents have extended medi...
Extracellular matrix-targeting oligonucleotide reverses marrow fibrosis
Abstract Myelofibrosis (MF) is a severe hematologic malignancy characterized by clonal stem cell-derived myeloproliferation, splenomegaly, a...
More than a bulk: Higher incidence of venous thromboembolism (VTE) in patients with primary mediastinal B-cell lymphoma compared to patients with bulky mediastinal Hodgkin lymphoma
Abstract Background: Primary mediastinal B-cell lymphoma (PMBCL) is a rare lymphoma subtype that typically affects young individuals, with a...
Allogeneic stem cell transplant following CAR T-cell therapy in relapsed/refractory adult acute lymphoblastic leukemia: A real-world analysis
Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a transformative treatment that induces high remission...
Single-cell immunophenotyping reveals mutation-specific immune alterations in severe congenital neutropenia
Abstract Introduction: Congenital defects in neutrophil number or function are associated with severe, recurrent infections often requiring...
Dose-adjusted treatment with venetoclax for 7 days and 5-azacitidine or decitabine in patients with Acute Myeloid Leukemia or higher risk myelodysplastic neoplasms
Abstract Introduction In patients unfit for intensive treatment, the combination of hypomethylating agents such as 5-azacitidine (AZA) or de...
Is autologous hematopoietic stem cell transplantation as consolidation therapy superior to chemotherapy alone in newly diagnosed intermediate-high risk DLBCL patients?
Abstract Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive B-cell lymphoma. Due to the use of Rituxim...
No reduction in gvhd risk for aplastic anemia patients to combined third-party unrelated cord blood in haploidentical hematopoietic stem cells transplantation
Abstract Background Aplastic anemia (AA) is a disease characterized by bone marrow failure. Allogeneic hematopoietic stem cell transplantati...
A multicenter phase 1 trial evaluating the safety and preliminary efficacy of revumenib as post-transplant maintenance after allogeneic hematopoietic cell transplant in patients with KMT2A-rearranged or NPM1-mutated acute leukemia
Abstract Background and Significance Allogeneic stem cell transplant (alloSCT) is a potentially curative post-remission therapy for patients...
Validation of the ELN2024 less-intensive prognostic stratification in newly diagnosed AML patients receiving venetoclax-azacitidine: A real-world study from China
Abstract Background: The recently issued ELN 2024 Less-Intensive risk stratification aims to refine prognosis for adults with acute myeloid...
Single-cell transcriptomics reveals monocytic glycolytic reprogramming in lymphoma-associated hemophagocytic lymphohistiocytosis
Abstract Background: Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a life-threatening hyperinflammatory syndrome with poo...
Real world data on the use of thrombopoietin receptor agonists in patients after allogeneic hematopoietic stem cell transplantation
Abstract Thrombocytopenia after allogeneic HSCT is known to be associated with increased morbidity and mortality. Although causes are not we...
PPM1D mutations confer resistance to venetoclax in pre-leukemic and AML populations
Abstract BACKGROUNDVenetoclax (VEN) combined with lower-intensity therapies are routinely used as first-line therapy for older AML patients...
Long-term safety and efficacy of iptacopan in patients with paroxysmal nocturnal hemoglobinuria: 4- and 5-year follow-up of patients from Phase 2 studies who entered the roll-over extension program
Abstract Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening disease characterized by complement-mediated hem...
Reversal of declining cardiac mortality trends in hemolytic anemia: National evidence from 1999 to 2023
Abstract Abstract Background: Hemolytic anemia encompasses a group of disorders defined by premature destruction of red blood cells and is i...
Identification of an optimal absolute lymphocyte count before bispecific antibody therapy for large B-cell lymphoma: A collaborative US bispecific consortium Study
Abstract Background: Currently approved in the third-line or later settings, anti-CD3xCD20 bispecific antibodies (BsAb) are increasingly uti...
Weight based dosing of alemtuzumab as part of an enhanced lymphodepletion regimen may mitigate the risks of over and underexposure and improve response rates : Analysis of the nathali-01 trial
Abstract Introduction: Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized treatment of refractory hematologic cancers, part...